The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 9396-9408

  Raupp, Christina ^a,d   Naumer, Matthias ^a   Müller, Oliver J ^b   Gurda, Brittney L ^c,e   Agbandje McKenna, Mavis ^c   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

^d ICON Clinical Research GmbH   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 2; ADENO ASSOCIATED VIRUS TYPE 8; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; POSTATTACHMENT PROCESSING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; RECEPTOR BINDING; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; TISSUE SPECIFICITY; VIRAL GENE DELIVERY SYSTEM; VIRAL PHENOMENA AND FUNCTIONS; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PROTRUSION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; CAPSID PROTEINS; CELL LINE; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE; MUS;

EID: 84866169735     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00209-12     Document Type: Article

References (91)

1. Akache B, et al. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80: 9831-9836.
2. Akache B, et al. 2007. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated viruses 2 and 8. Mol. Ther. 15: 330-339.
3. Asokan A, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28:79-82.
4. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80: 8961-8969.
5. Auricchio A. 2011. Fighting blindness with adeno-associated virus serotype 8. Hum. Gene Ther. 22: 1169-1170.
6. Bantel-Schaal U, Delius H, Schmidt R, and Hzur Hausen. 1999. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J. Virol. 73: 939-947.
7. Barbon CM, et al. 2005. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol. Ther. 12: 431-440.
8. Breous E, Somanathan S, Bell P, Wilson JM. 2011. Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology 141:348-355.
9. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. 2006. Adenoassociated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138:501-510.
10. Choi VW, McCarty DM, Samulski RJ. 2005. AAV hybrid serotypes: improved vectors for gene delivery. Curr. Gene Ther. 5: 299-310.
11. Daya S, Berns KI. 2008. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21: 583-593.
12. Denby L, Nicklin SA, Baker AH. 2005. Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther. 12: 1534-1538.
13. Dubielzig R, King JA, Weger S, Kern A, Kleinschmidt JA. 1999. Adenoassociated virus type 2 protein interactions: formation of pre-encapsidation complexes. J. Virol. 73: 8989-8998.
14. Gao G, et al. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78: 6381-6388.
15. Gao G, Vandenberghe LH, Wilson JM. 2005. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5: 285-297.
16. Gao GP, et al. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99: 11854-11859.
17. Gerlach B, Kleinschmidt JA, Bottcher B. 2011. Conformational changes in adeno-associated virus type 1 induced by genome packaging. J. Mol. Biol. 409: 427-438.
18. Ghosh A, et al. 2006. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther. 13: 321-329.
19. Girod A, et al. 1999. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nat. Med. 5: 1052-1056.
20. Govindasamy L, et al. 2006. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80: 11556-11570.
21. Gurda BL, Raupp C, Popa-Wagner R, Naumer M, Olson NH, Ng R, McKenna R, Baker TS, Kleinschmidt JA, Agbandje-McKenna M. 16 May 2012. Mapping a neutralizing epitope onto the capsid of adenoassociated virus serotype 8. J. Virol. doi:10.1128/JVI.00218-12.
22. Harding TC, et al. 2006. Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7-and AAV-8-pseudotyped vectors. Hum. Gene Ther. 17: 807-820.
23. Hoffman BE, et al. 2011. Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol. Ther. 19: 1263-1272.
24. Hosel M, et al. 2012. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55:287-297.
25. Humphrey W, Dalke A, Schulten K. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 8: 27-28.
26. Hurlbut GD, et al. 2010. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 18: 1983-1994.
27. Jayandharan GR, et al. 2011. Activation of the NF-κB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc. Natl. Acad. Sci. U. S. A. 108: 3743-3748.
28. Jiang H, et al. 2006. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108: 107-115.
29. Kern A, et al. 2003. Identification of a heparin-binding motif on adenoassociated virus type 2 capsids. J. Virol. 77: 11072-11081.
30. Laredj LN, Beard P. 2011. Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells. J. Virol. 85: 13133-13143.
31. Lerch TF, Chapman MS. 2012. Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology 423:6-13.
32. Levy HC, et al. 2009. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J. Struct. Biol. 165: 146-156.
33. Li H, et al. 2011. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol. Ther. 19: 2021-2030.
34. + T cells in mice. Mol. Ther. 19: 536-546.
35. Lochrie MA, et al. 2006. Mutations on the external surfaces of adenoassociated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80: 821-834.
36. Louboutin JP, Wang L, Wilson JM. 2005. Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 7: 442-451.
37. Manno CS, et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12: 342-347.
38. Martino AT, et al. 2011. The genome of self-complementary adenoassociated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117:6459-6468.
39. McEachern KA, et al. 2006. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J. Gene Med. 8: 719-729.
40. Michelfelder S, Trepel M. 2009. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 67: 29-60.
41. + T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13: 419-422.
42. Mori S, Wang L, Takeuchi T, Kanda T. 2004. Two novel adenoassociated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330:375-383.
43. Muller OJ, et al. 2003. Random peptide libraries displayed on adenoassociated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21: 1040-1046.
44. Murphy SL, Bhagwat A, Edmonson S, Zhou S, High KA. 2008. Highthroughput screening and biophysical interrogation of hepatotropic AAV. Mol. Ther. 16: 1960-1967.
45. Muzyczka N, and Warrington KH, Jr. 2005. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 16: 408-416.
46. Nakai H, et al. 2005. Large-scale molecular characterization of adenoassociated virus vector integration in mouse liver. J. Virol. 79: 3606-3614.
47. Nam HJ, et al. 2007. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81: 12260-12271.
48. Nathwani AC, et al. 2011. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther. 19: 876-885.
49. Nathwani AC, et al. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365: 2357-2365.
50. Ng R, et al. Structural characterization of the dual glycan binding adenoassociated virus serotype 6. J. Virol. 84:12945-12957.
51. Nietupski JB, et al. 2011. Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol. Ther. 19: 1999-2011.
52. O'Donnell J, Taylor KA, Chapman MS. 2009. Adeno-associated virus-2 and its primary cellular receptor-cryo-EM structure of a heparin complex. Virology 385:434-443.
53. Opie SR, Warrington KH, Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77: 6995-7006.
54. Pacak CA, et al. 2006. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99:e3-e9.
55. Passini MA, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120:1253-1264.
56. Paulk NK, et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51:1200-1208.
57. Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90: 8392-8396.
58. Perabo L, et al. 2003. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol. Ther. 8: 151-157.
59. Pien GC, et al. 2009. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119: 1688-1695.
60. Pulicherla N, et al. 2011. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19: 1070-1078.
61. Qiao C, et al. 2009. Hydrodynamic limb vein injection of adenoassociated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum. Gene Ther. 20: 1-10.
62. Rutledge EA, Halbert CL, Russell DW. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72: 309-319.
63. Sarkar R, et al. 2006. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum. Gene Ther. 17: 427-439.
64. Schmidt M, et al. 2008. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycanindependent transduction activity. J. Virol. 82: 1399-1406.
65. Shen X, Storm T, Kay MA. 2007. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol. Ther. 15: 1955-1962.
66. Shin O, Kim SJ, Lee WI, Kim JY, Lee H. 2008. Effective transduction by self-complementary adeno-associated viruses of human dendritic cells with no alteration of their natural characteristic. J. Gene Med. 10:762-769.
67. Snyder RO, Francis J. 2005. Adeno-associated viral vectors for clinical gene transfer studies. Curr. Gene Ther. 5: 311-321.
68. Sonntag F, et al. 2011. The assembly-activating protein (AAP) promotes capsid assembly of different AAV serotypes. J. Virol. 85: 12686-12697.
69. Sun B, et al. 2005. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11: 57-65.
70. Thomas CE, Storm TA, Huang Z, Kay MA. 2004. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78: 3110-3122.
71. Vandenberghe LH, Wilson JM, Gao G. 2009. Tailoring the AAV vector capsid for gene therapy. Gene Ther. 16: 311-319.
72. Veldwijk MR, et al. 2002. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6: 272-278.
73. Wang AY, Peng PD, Ehrhardt A, Storm TA, Kay MA. 2004. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum. Gene Ther. 15: 405-413.
74. Wang H, et al. 1998. Post-isolation inducible nitric oxide synthase gene expression due to collagenase buffer perfusion and characterization of the gene regulation in primary cultured murine hepatocytes. J. Biochem. 124: 892-899.
75. Wang L, et al. 2011. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol. Ther. 19: 2012-2020.
76. Wang L, et al. 2011. Impact of preexisting immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum. Gene Ther. 22: 1389-1401.
77. Wang Z, et al. 2005. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23: 321-328.
78. Waterkamp DA, Muller OJ, Ying Y, Trepel M, Kleinschmidt JA. 2006. Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8: 1307-1319.
79. Weger S, Wistuba A, Grimm D, Kleinschmidt JA. 1997. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep. proteins. J. Virol. 71: 8437-8447.
80. Wistuba A, Weger S, Kern A, Kleinschmidt JA. 1995. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69: 5311-5319.
81. Wobus CE, et al. 2000. Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74: 9281-9293.
82. Wu P, et al. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74: 8635-8647.
83. Xiao W, et al. 1999. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73: 3994-4003.
84. Xie Q, et al. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99: 10405-10410.
85. Xu D, Walker CM. 2011. Continuous CD8 T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery. J. Virol. 85: 12083-12086.
86. Ying Y, et al. 2010. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 17: 980-990.
87. Yu CY, et al. 2009. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther. 16: 953-962.
88. Zaiss AK, Muruve DA. 2008. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 15: 808-816.
89. Zhu J, Huang X, Yang Y. 2009. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest. 119: 2388-2398.
90. Zolotukhin S, et al. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6: 973-985.
91. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. 1996. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. 70: 4646-4654.